US equities
|
NVDA
$238.57
▲+1.97%
SPCX
$167.34
▲+5.27%
MU
$1,062.81
▼-1.12%
TSLA
$380.10
▲+2.56%
MSFT
$525.77
▲+1.59%
SNDK
$1,705.33
▼-0.85%
INTC
$117.11
▼-1.86%
META
$742.88
▲+2.03%
NVDA
$238.57
▲+1.97%
SPCX
$167.34
▲+5.27%
MU
$1,062.81
▼-1.12%
TSLA
$380.10
▲+2.56%
MSFT
$525.77
▲+1.59%
SNDK
$1,705.33
▼-0.85%
INTC
$117.11
▼-1.86%
META
$742.88
▲+2.03%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
6.340
+0.120 (+1.93%)
Delayed Quote
Updated: 2:38 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kyverna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
December 17, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Lost Money on Kyverna Therapeutics, Inc.(KYTX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
December 17, 2024
Via
ACCESSWIRE
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX
December 16, 2024
Via
ACCESSWIRE
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) Seeking Recovery for Investors – Contact Levi & Korsinsky
December 16, 2024
Via
ACCESSWIRE
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
December 16, 2024
Via
ACCESSWIRE
The Schall Law Firm Urges Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
December 16, 2024
Via
ACCESSWIRE
Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
December 16, 2024
Via
ACCESSWIRE
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
December 16, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
December 16, 2024
Via
ACCESSWIRE
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
December 16, 2024
Via
ACCESSWIRE
KYTX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
December 16, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Kyverna Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Contact The Schall Law Firm
December 15, 2024
Via
ACCESSWIRE
KYTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
December 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
December 15, 2024
Via
ACCESSWIRE
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc.(KYTX) of a Class Action Lawsuit and an Upcoming Deadline
December 15, 2024
Via
ACCESSWIRE
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
December 15, 2024
Via
ACCESSWIRE
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join – Contact Levi & Korsinsky
December 14, 2024
Via
ACCESSWIRE
The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
December 14, 2024
Via
ACCESSWIRE
Kyverna Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
December 14, 2024
Via
ACCESSWIRE
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – KYTX
December 14, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
December 13, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Kyverna Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm
December 13, 2024
Via
ACCESSWIRE
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
December 13, 2024
Via
ACCESSWIRE
Kyverna Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the KYTX Class Action Lawsuit
December 13, 2024
From
Robbins LLP
Via
GlobeNewswire
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX
December 13, 2024
Via
ACCESSWIRE
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
December 13, 2024
Via
ACCESSWIRE
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
December 12, 2024
Via
ACCESSWIRE
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join – Contact Levi & Korsinsky
December 12, 2024
Via
ACCESSWIRE
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
December 12, 2024
Via
ACCESSWIRE
The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
December 12, 2024
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
Next >
